Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.48 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL15667959 | 1.00 | MAPK1 (0.54) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL7113626 | 0.97 | MAPT (0.50) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL1066768 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL571428 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL17003748 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL440983 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL136431 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL9503022 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL9055250 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE | |
| SCHEMBL1340807 | 0.94 | MAPT (0.60) | MAPK1MAPTLMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023123986-A1 | UTIDELONE LIPOSOME COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都华昊中天药业有限公司 | 2023-07-06 | — | — | WO | claimed |
| US-8192753-B2 | pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same | MARINA BIOTECH, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20060002991-A1 | Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same | NOVOSOM VERWALTUNGS GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060002991-A1 | Ph-sensitive cationic lipids, and liposomes and nanocapsules containing the same | LPAR5, LIPA, SGMS2 | MAPK1 2119/4885MAPT 4490/4885LMNA 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.